Grace Therapeutics (FRA:L8S) Cyclically Adjusted Book per Share: €12.81 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:L8S Grace Therapeutics Inc FRA:L8S
31 GF Score
Price €2.78
! 2 Warning Signs
View Full Analysis

What is Grace Therapeutics Cyclically Adjusted Book per Share?

Grace Therapeutics FRA:L8S 31 Cyclically Adjusted Book per Share is €12.81 as of Mar. 2026. GuruFocus rates FRA:L8S with a GF Score™ of 31/100. The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Grace Therapeutics's adjusted book value per share for the three months ended in Mar. 2026 was €3.449. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €12.81 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Grace Therapeutics's average Cyclically Adjusted Book Growth Rate was -39.30% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -29.40% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -16.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Grace Therapeutics was 5.70% per year. The lowest was -29.40% per year. And the median was -1.00% per year.

As of today (2026-07-14), Grace Therapeutics's current stock price is €2.78. Grace Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was €12.81. Grace Therapeutics's Cyclically Adjusted PB Ratio of today is 0.22.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Grace Therapeutics was 0.94. The lowest was 0.03. And the median was 0.06.


Grace Therapeutics  (FRA:L8S) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Grace Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=2.78/12.81
=0.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Grace Therapeutics was 0.94. The lowest was 0.03. And the median was 0.06.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Grace Therapeutics Cyclically Adjusted Book per Share Related Terms


Grace Therapeutics Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Grace Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Grace Therapeutics Cyclically Adjusted Book per Share Chart

Grace Therapeutics Annual Data
Trend Feb16 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 52.17 48.06 46.88 42.83 12.81

Grace Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 42.83 29.41 25.91 19.44 12.81

FRA:L8S vs INMB, ABVC, NTRB: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Grace Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Grace Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Grace Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Grace Therapeutics's Cyclically Adjusted PB Ratio falls into.


FRA:L8S
31GF Score
Grace Therapeutics Inc FRA:L8S
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Grace Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Grace Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=3.449/330.2130*330.2130
=3.449

Current CPI (Mar. 2026) = 330.2130.

Grace Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201602 81.247 237.111 113.149
201605 73.345 240.229 100.818
201608 67.256 240.849 92.210
201611 61.170 241.353 83.691
201706 42.303 244.955 57.027
201709 32.616 246.819 43.636
201712 19.799 246.524 26.520
201803 9.670 249.554 12.795
201806 6.431 251.989 8.427
201809 -12.870 252.439 -16.835
201812 12.139 251.233 15.955
201903 6.004 254.202 7.799
201906 1.460 256.143 1.882
201909 -0.645 256.759 -0.830
201912 -2.324 256.974 -2.986
202003 6.259 258.115 8.007
202006 5.086 257.797 6.515
202009 3.733 260.280 4.736
202012 6.500 260.474 8.240
202103 10.770 264.877 13.427
202106 10.221 271.696 12.422
202109 13.152 274.310 15.832
202112 13.317 278.802 15.773
202203 13.319 287.504 15.298
202206 13.318 296.311 14.842
202209 13.607 296.808 15.138
202212 12.280 296.797 13.663
202303 8.537 301.836 9.340
202306 7.945 305.109 8.599
202309 6.654 307.789 7.139
202312 6.310 306.746 6.793
202403 6.044 312.332 6.390
202406 5.439 314.175 5.717
202409 4.988 315.301 5.224
202412 4.911 315.605 5.138
202503 4.491 319.799 4.637
202506 3.984 322.561 4.079
202509 3.788 324.800 3.851
202512 3.581 324.054 3.649
202603 3.449 330.213 3.449

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €12.81 mean?
Grace Therapeutics (FRA:L8S) has a Cyclically Adjusted Book per Share of €12.81 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Grace Therapeutics and its competitors.
Is Grace Therapeutics' Cyclically Adjusted Book per Share too high?
Grace Therapeutics' current Cyclically Adjusted Book per Share is €12.81. Overall, Grace Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Grace Therapeutics' Cyclically Adjusted Book per Share compare to INMB and ABVC?
Grace Therapeutics' Cyclically Adjusted Book per Share of €12.81 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Grace Therapeutics and its competitors. Grace Therapeutics's current Cyclically Adjusted Book per Share is €12.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grace Therapeutics stock overvalued right now?
Grace Therapeutics (FRA:L8S) has a current Cyclically Adjusted Book per Share of €12.81. The current Cyclically Adjusted Book per Share is €12.81. Grace Therapeutics' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Grace Therapeutics (FRA:L8S), the current Cyclically Adjusted Book per Share is €12.81 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Grace Therapeutics Business Description

Other Exchanges GRCE:USA
Address 103 Carnegie Center, Suite 300, Princeton, NJ, USA, 08540
Grace Therapeutics Inc is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its development pipeline consists of the following product candidates: GTx-104, a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage (aSAH); GTx-102, targeted for the treatment of ataxia-telangiectasia (A-T) in a pediatric population; and GTx-101, a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia (PHN), which can be persistent and often causes debilitating pain following infection by the shingles virus. The company has one reportable operating segment: the development and commercialization of pharmaceutical applications of its patents and licensed rights.
31GF Score

Get the complete analysis for FRA:L8S

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.78
Price